top of page
Search

Multilingual SEO for Pharma: Languages, FDA Rules, Vendor Duties

1 day ago
10 min read

Reviewing localized pharma patient education content

Direct answer. Multilingual SEO for a U.S. pharmaceutical company means building separate, crawlable language versions of approved content, researching search intent in each language, and localizing titles and metadata without changing approved claims. Each version needs correct hreflang annotations, regulatory review, and a vendor that enforces access control, audit trails and QA on protected content.



Table of Contents

 

 

What does multilingual SEO mean for a pharma company?

 

Multilingual SEO is the practice of making a website discoverable in search engines in more than one language. For pharma it covers corporate pages, disease education, product information, clinical trial recruitment pages and patient materials.

 

It requires more than translating an English site. Search behavior differs by language. Approved terminology differs by market. Claims that are permitted in one country may be restricted in another. Metadata, headings, structured data and internal links all carry claims, so each is a regulated text, not a technical field.

 

Two terms are used in this article.

 

  • Multilingual site: a site with content in more than one language.

  • Multiregional site: a site that targets users in different countries.

 

Google Search Central distinguishes the two. A pharma site is often both, because country versions can offer different language sets and different product ranges.

 

This article is written for localization, SEO, regulatory and security leads in pharma, biotech and medical device companies. It covers U.S. rules where promotion is concerned. Rules of other jurisdictions must be checked against their own official sources.

 

Scope: what is and is not covered

 

In scope:

 

  • Website pages, titles, meta descriptions, headings, alt text, schema markup and URL slugs.

  • Prescription drug, biologic and device content published by or for a U.S. company.

  • Content that contains product claims, risk information or patient instructions.

  • Data handled by the translation workflow, including unpublished drafts and confidential product information.

 

Out of scope: paid search policies, local pharmacovigilance reporting rules and non-U.S. advertising codes. Those need a market-specific regulatory review.

 

Machine translation (MT) and neural machine translation (NMT) are not treated here as AI translation. They are engines that output text without defined human review. The workflow described below uses an AI+HUMAN hybrid model, where AI output is reviewed and corrected by subject-matter experts under a quality process.

 

How should a pharma company choose languages and markets?

 

Start with demand and obligation, in that order.

 

  1. Owner: Global SEO lead with commercial and regulatory leads. List the markets where the product is approved or where corporate and investor content is needed.

  2. Control: market approval register. Publish no product content for a market where the product has no authorization, unless regulatory affairs confirms the content is permitted.

  3. Owner: Global SEO lead. Check search demand by language, not only by country. A 2007 study in the Journal of Medical Internet Research found that people often searched for health information in their local language, and it supplied search-pattern data to help choose languages for health websites. The data is old. Current volumes must come from current keyword tools and search console data.

  4. Owner: Localization lead. Decide between language targeting and country targeting. Spanish content for U.S. readers and Spanish content for Spain are different projects with different regulatory contexts.

  5. Control: keyword research by native-speaking subject-matter experts. Direct translation of English keywords often misses the terms that patients and clinicians actually type. Patients use lay terms. Clinicians use clinical terms. Both audiences need separate pages or clearly separated sections.

 

For the U.S. market, the practical case is often Spanish and other widely spoken languages for patient-facing content, plus the languages of the markets where the company files or sells.

 

How are titles, metadata and content localized without losing accuracy?

 

Localized SEO text must stay consistent with approved source text. The workflow has five steps.

 

  1. Freeze the source. Owner: regulatory affairs. Control: version-controlled approved master content. Only approved text enters translation.

  2. Build a term base. Owner: localization lead. Control: a governed glossary of approved drug names, indications, risk terms and device names, per language. Translation memories and term bases are loaded into the workflow so earlier approved wording is reused.

  3. Localize search elements. Owner: SEO lead with a subject-matter linguist. Title tags, meta descriptions, headings and anchor text are written for each language. They may not add efficacy claims, remove risk context or imply an unapproved use.

  4. Review. Owner: medical, legal and regulatory reviewers. Control: documented review record. Back-translation or bilingual review is used for claim-bearing text.

  5. Publish with traceability. Owner: web operations. Control: audit trail that links each published page to its approved source version and reviewer.

 

Patient instructions need extra care. The FDA guidance on Instructions for Use (July 2022) says IFUs for human prescription drug and biological products must be consistent with the approved Prescribing Information. It asks for nontechnical language at or below the national average reading level, active voice, no abbreviations and no trailing zeros in dose designations, to prevent medication errors. Those expectations apply to the English text. A localized version should keep the same dose notation and the same plain-language intent, and reviewers should check that a search-friendly title does not alter the instruction.

 

How should URL structure, hreflang and canonicals be set up?

 

Technical setup decides whether localized pages are found at all.

 

  • Separate URLs per language. Google recommends separate URLs for each language version instead of switching language with cookies or browser settings, because dynamic variations may not all be discovered and crawled. Subdirectories (example.com/es/), subdomains and country-code domains are all workable. Pick one pattern and keep it.

  • Hreflang annotations. According to Google’s localized-versions documentation, hreflang identifies localized alternatives. Every version should reference itself and all other versions, and annotations need complete URLs.

  • Language and region codes. The same documentation states that values use ISO 639-1 language codes, optionally followed by an ISO 3166-1 Alpha-2 region code. A country code cannot be used alone. Use es-US for Spanish for U.S. readers and es-ES for Spain.

  • Canonicals. Each language page should canonicalize to itself. Pointing a translated page’s canonical at the English page removes the translation from consideration.

  • Sitemaps and internal links. Link language versions to each other and keep one sitemap entry per version.

 

Teams that handle hreflang by hand on large regulated sites often benefit from a technical reference. A guide to technical SEO for language and regional versions covers site structure points relevant to healthcare sites. A separate article on hreflang implementation without errors describes how mismatched annotations create discoverability risk in another regulated sector.

 

Which FDA and FTC rules apply to promotional content found through search?

 

Search visibility does not create exemptions. A localized page is promotional content when it promotes a product, in any language. The U.S. rules below are the baseline for content aimed at U.S. audiences.

 

Source

What it requires

Relevance to multilingual SEO

Prescription-drug advertisements give a true brief summary of side effects, contraindications and effectiveness, subject to listed exceptions. They may not be false or misleading or lack fair balance.

Spanish or other U.S.-targeted pages that promote a drug need the same risk information as English pages.

21 CFR 202.1 (same source)

Effectiveness information may not be presented with greater scope, depth or detail than risk information unless a comparably detailed risk presentation fairly balances it.

A localized meta description that states a benefit with no risk context creates a balance question.

Prescription-drug advertising requirements apply regardless of the audience targeted. The FD&C Act requires brief-summary information.

Patient-facing and clinician-facing pages are both covered.

Health advertising must be truthful and not misleading. Advertisers need adequate substantiation before disseminating objective claims, express or implied.

Translated claims need the same substantiation as the source claim.

What changed in the last two years?

 

The main recent change is the FDA’s Clear, Conspicuous, and Neutral (CCN) rule. It applies to human prescription-drug ads presented directly to consumers in television or radio format that name the drug and its conditions of use. It became effective on May 20, 2024, and covered firms had until November 20, 2024, to comply. The rule governs how the major risk statement is presented. It does not change the required content.

 

FDA materials from June 2024 describe the rule as covering DTC television and radio ads. It is not a universal new standard for ordinary organic search listings. Companies that repurpose broadcast scripts as web video transcripts or localized video pages should have regulatory affairs confirm which rules apply to each asset.


What changed in the last two years?

What are the decision criteria for choosing a localization vendor?

 

Use criteria that can be verified from documents and audits.

 

Criterion

What to verify

Control

Quality management

ISO 9001 and ISO 17100 certificates

Independent audit report

MT post-editing

ISO 18587 certification for post-editing

Documented post-editing procedure

Medical device scope

ISO 13485 where device content is included

Certificate scope statement

Information security

ISO 27001 certificate and hosting location

Access control list, encryption, audit trail

AI governance

ISO 42001 certificate

AI use policy and model documentation

Data protection

GDPR and HIPAA alignment

Data processing agreement, role-based access

Expertise

Linguists with medical, legal or engineering backgrounds

Linguist qualification records

Terminology

Use of client translation memories and term bases

Terminology governance process

SEO capability

Keyword research by language and metadata localization

Deliverable list per language

The security row matters for pre-launch content. Unpublished product names, trial information and draft labeling should not pass through public tools with unclear data handling. The CISO should confirm where processing occurs and who can read the files.

 

Examples

 

Example 1: Spanish patient education pages in the U.S. A company has an approved English page on a chronic condition. Keyword research in Spanish shows that patients search with lay terms that differ from the translated clinical term. The team writes a Spanish title using the lay term and keeps the approved clinical term in the body. Medical and regulatory reviewers approve both. The page uses an es-US hreflang value and links to the English page.

 

Example 2: A product page with different availability. A biologic is approved in the U.S. and in two other markets, with different indications. Each country page is separate. The metadata lists only the indications approved in that market. Country pages do not share a canonical.

 

Example 3: Device instructions. A device manufacturer localizes an instructions-for-use page. The dose and unit notation stay identical to the approved source. The title tag is localized for search, and a reviewer checks it against the labeling.


Examples

Failure modes and mitigations

 

The Attico Pharma Benchmark (April 2026) found that 66.7% of top-tier pharma sites remain monolingual. Among the multilingual sites, 61.5% showed a clean implementation, hreflang errors appeared in 38.5% of cases, and 38.5% fell into the Low AI visibility group, against 15.4% of non-multilingual sites. The authors also note that a 50% issue rate in structured data among sites with markup is a critical problem where AI discoverability depends on parsing.

 

Failure mode

Effect

Mitigation

Owner

Hreflang missing return links

Language versions are not paired

Automated hreflang validation on each release

SEO lead

Country code used alone

Annotation is invalid

Use language code first, region second

Web operations

Translated metadata adds a claim

Promotional compliance issue

Regulatory review of all metadata

Regulatory affairs

Risk text missing on localized page

Fair balance problem

Template that locks risk module to every promotional page

Compliance

Inconsistent drug terms across pages

Trust loss, confusion

Governed term base

Localization lead

Broken structured data in translation

Parsing errors for search and AI systems

Schema validation per language

SEO lead

Confidential drafts in public tools

Data exposure

Private hosting, access control, audit trail

CISO

No measurement per language

Problems go unseen

Separate reporting by language and country

Analytics

Measure each language version separately. Useful indicators are indexed pages, impressions and clicks by language, hreflang error counts from Search Console, structured data validity, and visibility in AI-generated answers.

 

Where AD VERBUM fits

 

AD VERBUM is a language service provider with 25+ years of experience. Its AI+HUMAN hybrid translation runs on a proprietary LangOps System hosted on EU servers, supports 150+ languages including regional variants, and integrates client translation memories and term bases. Subject-matter expert linguists review output. Its certifications include ISO 17100, ISO 18587, ISO 13485, ISO 27001 and ISO 42001, audited by Bureau Veritas. Multilingual SEO is among its listed services.


AD VERBUM

Perspective

 

In our work, the weak point in pharma multilingual SEO is rarely the translation of body text. It is the small text around it: title tags, meta descriptions, alt text and schema fields. These strings are short, they are written last, and they often skip review.   We treat them as claim-bearing content. Our AI+HUMAN hybrid process places subject-matter experts, many with medical backgrounds, over the AI output. Client term bases and translation memories keep drug names and risk language identical across pages and languages.   Security belongs in the same conversation. Unpublished product content should stay on private infrastructure with defined access control and an audit trail. That is why our LangOps System is hosted on EU servers and held to ISO 27001 and ISO 42001.   Search teams and regulatory teams should agree on one approved source, one glossary and one review record per language before the first page goes live.   Eric Brown

 

Key points

 

  • Multilingual SEO for pharma is a regulated content process, not a translation task.

  • Choose languages by search demand, market authorization and regulatory capacity.

  • Use separate URLs per language and valid hreflang values with self-reference and return links.

  • Treat titles, meta descriptions and schema as promotional text that needs review.

  • Keep risk information and fair balance on every localized promotional page.

  • The 2024 CCN rule concerns DTC television and radio ads, not ordinary organic listings.

  • Require access control, audit trails and QA from every vendor that touches unpublished content.

  • Report SEO performance per language and per country.

 

FAQ

 

Does Google penalize translated pharma pages?

 

Google does not penalize a page only because it is translated. The page must be useful, correct and technically discoverable. Use separate URLs, valid hreflang and reviewed text, and have each language version approved before publication.

 

Do FDA rules apply to Spanish-language pages for U.S. readers?

 

Yes, where the page promotes a prescription drug. The FDA OPDP states that advertising requirements apply regardless of the audience targeted. Risk information and fair balance must carry over to the localized version. Regulatory affairs should confirm the specific requirements for each asset.

 

Which hreflang value should be used for Spanish content in the United States?

 

Use es-US. Google documents that hreflang takes an ISO 639-1 language code, optionally followed by an ISO 3166-1 Alpha-2 region code. A country code cannot stand alone. Each version should reference itself and every alternate with complete URLs.

 

Who should own multilingual SEO in a pharma company?

 

The global SEO lead owns the technical and keyword work. Regulatory affairs owns claim approval. The localization lead owns the glossary and vendor workflow. The CISO owns data handling requirements. A written responsibility matrix prevents gaps between these roles.

 

Sources

 

 
 
bottom of page